Pfizer Starna Deal: $330M Upfront Buys Into In Vivo CAR-T for Autoimmune Disease
Pfizer is paying Starna Therapeutics $330 million upfront, with up to $2.3 billion in milestones, for three preclinical in vivo CAR-T programs in autoimmune disease. Terms, science and risks explained.
